+

WO2011098799A3 - Traitement de maladie respiratoire - Google Patents

Traitement de maladie respiratoire Download PDF

Info

Publication number
WO2011098799A3
WO2011098799A3 PCT/GB2011/050224 GB2011050224W WO2011098799A3 WO 2011098799 A3 WO2011098799 A3 WO 2011098799A3 GB 2011050224 W GB2011050224 W GB 2011050224W WO 2011098799 A3 WO2011098799 A3 WO 2011098799A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
ethoxy
benzyl
hydroxy
ethyl
Prior art date
Application number
PCT/GB2011/050224
Other languages
English (en)
Other versions
WO2011098799A2 (fr
Inventor
Harry Finch
Craig Fox
Original Assignee
Pulmagen Therapeutics (Inflammation) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmagen Therapeutics (Inflammation) Limited filed Critical Pulmagen Therapeutics (Inflammation) Limited
Publication of WO2011098799A2 publication Critical patent/WO2011098799A2/fr
Publication of WO2011098799A3 publication Critical patent/WO2011098799A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique contenant le composé 5-{4-[2-(5-éthyl-pyridin-2-yl)-2-hydroxy-éthoxy]-benzyl}-thiazolidine-2,4-dιone ou un sel pharmaceutiquement acceptable de ce dernier ainsi qu'un ou plusieurs véhicules et/ou excipients. La composition est caractérisée en ce qu'au moins 95% en poids de la teneur en 5-{4-[2-(5-éthyl-pyridin-2-yl)-2- hydroxy-éthoxy]-benzyl}-thiazolidine-2,4-dione de la composition est la forme diastéréomère 5(R)-{4-[2-(5-éthyl-pyridin-2-yI)=2(S)-hydroxy-éthoxy]=benzyl}- thiazolidιne-2,4-dione et en ce que moins de 5% en poids est constitué d'une ou plusieurs des trois formes diastéréomères.
PCT/GB2011/050224 2010-02-10 2011-02-09 Traitement de maladie respiratoire WO2011098799A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1002224.2 2010-02-10
GBGB1002224.2A GB201002224D0 (en) 2010-02-10 2010-02-10 Respiratory disease treatment

Publications (2)

Publication Number Publication Date
WO2011098799A2 WO2011098799A2 (fr) 2011-08-18
WO2011098799A3 true WO2011098799A3 (fr) 2015-09-11

Family

ID=42110492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/050224 WO2011098799A2 (fr) 2010-02-10 2011-02-09 Traitement de maladie respiratoire

Country Status (2)

Country Link
GB (1) GB201002224D0 (fr)
WO (1) WO2011098799A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
CA2941562C (fr) 2013-03-14 2021-09-21 Deuterx, Llc 2,4-thiazolidinediones enrichies en deuterium et methodes de traitement
EP3094328B1 (fr) 2014-01-15 2020-08-19 Poxel SA Méthodes de traitement de troubles neurologiques, métaboliques et autres à l'aide de pioglitazone énantiopure enrichie en deutérium
AU2015315455A1 (en) * 2014-09-08 2017-04-27 Gotham Biopharmaceuticals, Inc. Mucolytic agents for use in tretaing pulmonary sarcoidosis
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109088A2 (fr) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Therapies d'association d'analogues de la thiazolidinedione
WO2010015818A1 (fr) * 2008-08-07 2010-02-11 Argenta Discovery Limited Traitement de maladie respiratoire
WO2010150014A1 (fr) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6235216A (ja) 1985-08-09 1987-02-16 Noritoshi Nakabachi 不均質物質層の層厚非破壊測定方法および装置
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
WO1993018007A1 (fr) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
WO2000021143A1 (fr) 1998-10-05 2000-04-13 Osram Opto Semiconductors Gmbh & Co. Ohg Puce semi-conductrice emettant des rayonnements
SI20116A (sl) 1998-12-02 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov postopek za pripravo simvastatina in njegovih analogov
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
AU5629301A (en) 2000-04-27 2001-11-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel, slow-acting betamimetics, a method for their production and their use as medicaments
DE10346940B3 (de) 2003-10-06 2005-06-16 Schering Ag Substituierte Pentanole, ihre Verwendung zur Herstellung von Arzneimitteln speziell Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate
EP1305330B1 (fr) 2000-08-05 2008-12-03 Glaxo Group Limited Derives de 17-beta-carbothioate-17-alpha-arylcarbonyloxyloxy androstane utilises comme anti-inflammatoires
AU2001288271A1 (en) 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
DE60220887T2 (de) 2001-03-08 2008-02-28 Glaxo Group Ltd., Greenford Agonisten von beta-adrenorezeptoren
JP4143413B2 (ja) 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
DE60227254D1 (de) 2001-06-12 2008-08-07 Glaxo Group Ltd Neue anti inflammatorische 17.alpha.-heterozyklische ester von 17.beta.-carbothioat androstan derivativen
PT1425001E (pt) 2001-09-14 2009-02-18 Glaxo Group Ltd Derivados de fenetanolamina para o tratamento de doenças respiratórias
WO2003042229A1 (fr) 2001-11-12 2003-05-22 Glaxo Group Limited Esters heterocycliques non aromatiques de furan-2-one esters de 17 $g(b) carboxyl ou 17 $g(b) carbothio glucocorticoides
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (fr) 2001-11-13 2003-05-22 Theravance, Inc. Agonistes de recepteur d'aryl aniline beta-2 adrenergique
WO2003048181A1 (fr) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha.-esters cycliques de 16-methylpregnan-3,20-dione en tant qu'agents anti-inflammatoires
WO2003062259A2 (fr) 2002-01-21 2003-07-31 Glaxo Group Limited Nouveaux composes
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
ATE381535T1 (de) 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate
EP1507754A1 (fr) 2002-05-28 2005-02-23 Theravance, Inc. Agonistes du recepteur adrenergique beta 2 alcoxy aryle
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040962A1 (es) 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
AP2005003283A0 (en) 2002-10-11 2005-06-30 Pfizer Indole derivatives useful for the treatment os diseases
EP1440966A1 (fr) 2003-01-10 2004-07-28 Pfizer Limited Dérivés d'indole utilisables pour traiter des maladies
DE60315492T2 (de) 2002-10-22 2008-04-24 Glaxo Group Ltd., Greenford Medizinisch verwendbare arylethanolamin verbindungen
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
ES2302956T3 (es) 2002-10-28 2008-08-01 Glaxo Group Limited Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias.
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10258695A1 (de) 2002-12-16 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neuer, langwirksamer Beta-agonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
EP1460064A1 (fr) 2003-03-14 2004-09-22 Pfizer Limited Derivés de Indole-2-carboxamide comme beta-2 agonistes
WO2004089892A2 (fr) 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyle et composes apparentes
EP1613315B1 (fr) 2003-04-04 2009-01-21 Novartis AG Derives de quinoline-2-one permettant de traiter des maladies des voies respiratoires
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
EP1477167A1 (fr) 2003-05-15 2004-11-17 Pfizer Limited Dérivés de [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl come agonistes de beta2
ES2329133T3 (es) 2003-05-28 2009-11-23 Theravance, Inc. Compuestos azabicicloalcanicos como antagonistas de receptores de muscarinicos.
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
JP2006526604A (ja) 2003-06-04 2006-11-24 ファイザー・インク β−２アドレナリン受容体アゴニストとしての２−アミノ−ピリジン誘導体
JP2008529963A (ja) 2003-07-01 2008-08-07 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 複素環式−置換されたペンタノール誘導体類、それらの生成方法及び抗炎症剤としてのそれらの使用
WO2005033121A2 (fr) 2003-10-03 2005-04-14 King Pharmaceuticals Research & Development, Inc. Synthese de 2-aralkyloxyadenosines, 2-alkoxyadenosines, et leurs analogues
DE10347385A1 (de) 2003-10-08 2005-05-12 Schering Ag Umgelagerte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
PL1670458T3 (pl) 2003-10-08 2007-05-31 Bayer Schering Pharma Ag 1-amino-2-hydroksy-podstawione pochodne tetrahydronaftalenu, sposób ich wytwarzania i ich zastosowanie jako środków hamujących zapalenie
GB0323701D0 (en) 2003-10-09 2003-11-12 Glaxo Group Ltd Formulations
GB0324654D0 (en) 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0328490D0 (en) 2003-12-09 2004-01-14 Glaxo Group Ltd Medicinal compounds
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
US7674368B2 (en) 2003-12-19 2010-03-09 Shell Oil Company Systems, methods, and catalysts for producing a crude product
DE102004001413A1 (de) 2004-01-09 2005-08-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
AU2005214153B2 (en) 2004-01-22 2008-09-18 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
AU2005214154B2 (en) 2004-01-22 2008-01-24 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
DE102004003428A1 (de) 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel
ATE479433T1 (de) 2004-02-14 2010-09-15 Boehringer Ingelheim Int Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
WO2005092861A1 (fr) 2004-03-11 2005-10-06 Pfizer Limited Derives de quinolinone compositions pharmaceutiques contenant ces derives et utilisation de celles-ci
EP1577292A1 (fr) 2004-03-17 2005-09-21 Pfizer Limited Dérivées de phenylaminoethanol comme agonistes des recepteurs beta2
EP1577306A1 (fr) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG nouveaux dérivés de Benzoxazinone comme béta-mimétiques de longue durée et leur utilisation pour le traitement des maladies des voies respiratoires
HN2004000023A (es) 2004-03-22 2007-11-23 Mars Inc Mascadura para animales
WO2005092841A1 (fr) 2004-03-23 2005-10-06 Pfizer Limited Composes presentant une activite beta-agoniste
EP1730103B1 (fr) 2004-03-23 2010-05-26 Pfizer Limited Derives du formamide utile comme adrenocepteur
WO2005092860A1 (fr) 2004-03-23 2005-10-06 Pfizer Limited Composes servant au traitement de maladies
EA200601462A1 (ru) 2004-03-23 2007-04-27 Пфайзер Инк. Соединения для лечения заболеваний
EP1595873A1 (fr) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Dérivés de cycloalkyle pour le traitement des maladies respiratoires
JP2007537187A (ja) 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024451A1 (de) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
BRPI0511695A (pt) 2004-06-03 2008-01-08 Theravance Inc agonistas de receptor (beta)2 adrenérgico diamina
EP1778638A1 (fr) 2004-07-21 2007-05-02 Theravance, Inc. Agonistes des recepteurs beta2 adrenergiques derives d'ethers de diaryle
WO2006016245A1 (fr) 2004-08-05 2006-02-16 Ranbaxy Laboratories Limited Antagonistes des récepteurs muscariniques
JP2008512470A (ja) 2004-09-10 2008-04-24 セラヴァンス， インコーポレーテッド アミジン置換アリールアニリン化合物
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
WO2006051373A1 (fr) 2004-11-12 2006-05-18 Pfizer Limited Composes permettant de traiter de maladies
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
TW200745099A (en) 2006-03-02 2007-12-16 Sankyo Co Optically active thiazolidinedione derivatives
CA2646207C (fr) 2006-03-16 2016-01-19 Metabolic Solutions Development Company Analogues de la thiazolidinedione
GB0702459D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 669
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
GB0704000D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109088A2 (fr) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Therapies d'association d'analogues de la thiazolidinedione
WO2010015818A1 (fr) * 2008-08-07 2010-02-11 Argenta Discovery Limited Traitement de maladie respiratoire
WO2010150014A1 (fr) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JAMALI B ET AL: "Investigation of racemisation of the enantiomers of glitazone drug compounds at different pH using chiral HPLC and chiral CE", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, NEW YORK, NY, US, vol. 46, no. 1, 7 January 2008 (2008-01-07), pages 82 - 87, XP002587887, ISSN: 0731-7085, [retrieved on 20070910], DOI: DOI:10.1016/J.JPBA.2007.09.004 *
NARALA VENKATA R ET AL: "Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma", RESPIRATORY RESEARCH, BIOMED CENTRAL LTD., LONDON, GB, vol. 8, no. 1, 4 December 2007 (2007-12-04), pages 90, XP021031353, ISSN: 1465-9921 *
PARKS D J ET AL: "Differential activity of rosiglitazone enantiomers at PPARgamma", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 8, no. 24, 15 December 1998 (1998-12-15), pages 3657 - 3658, XP004819411, ISSN: 0960-894X, DOI: DOI:10.1016/S0960-894X(98)00664-7 *
TANIS S P ET AL: "Synthesis and biological activity of metabolites of the antidiabetic antihyperglycemic agent Pioglitazone", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 39, no. 26, 1 January 1996 (1996-01-01), pages 5053 - 5063, XP002336054, ISSN: 0022-2623, DOI: DOI:10.1021/JM9605694 *

Also Published As

Publication number Publication date
WO2011098799A2 (fr) 2011-08-18
GB201002224D0 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
GB2465897A (en) Respiratory disease treatment
WO2011098799A3 (fr) Traitement de maladie respiratoire
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2007082808A3 (fr) Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
WO2010068810A3 (fr) Amides substitués, et leurs procédés de production et d'utilisation
WO2009010416A3 (fr) Inhibiteurs de 11b-hydroxystéroïde déshydrogenase
WO2009039397A3 (fr) Amides substitués, procédé pour les préparer et procédé pour les utiliser
NZ594332A (en) Compounds for the prevention and treatment of cardiovascular disease
NZ596154A (en) Cyclic compound having substituted phenyl group
WO2012032360A3 (fr) Nouvelle utilisation de composés biologiquement actifs
NO20091501L (no) Farmasoytiske sammensetninger
NZ582089A (en) Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
PH12013502277A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
IL205974A (en) 2- (5-Bromo-4- (4-Cyclopropylphenaphthalene-1-ram) -4 h-4,2,1- Triazole-3-Ilthio) Acetic acid or salt is acceptable in its pharmacy for use as a drug and a pharmaceutical preparation containing this compound
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
WO2008137779A3 (fr) Inhibiteurs macrocycliques innovants de la réplication du virus de l'hépatite c
HK1138277A1 (en) Prophylactic and/or therapeutic agent for hyperlipemia
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
WO2010088000A3 (fr) Composés antifibrotiques et leurs utilisations
WO2012001074A3 (fr) Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydraté
EP3276004A3 (fr) Procédés de traitement d'une maladie rénale chronique
UA111599C2 (uk) Композиція каспофунгіну
IL230487B (en) 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them
EA200701681A1 (ru) Пероральная лекарственная форма, содержащая росиглитазон
EP1774968A4 (fr) Dérivé de benzylisoquinoléine - ou dérivé bisbenzylisoquinoléine - contenant un agent psychotrope, analgésique et/ou antiphlogistique, et aliment de santé.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11703726

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11703726

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载